50 results on '"Murakami, Mark A"'
Search Results
2. A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).
3. Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma
4. CTIM-37. A PILOT STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL AND SCNSL)
5. CTIM-39. A PHASE 1B STUDY OF PEMBROLIZUMAB, IBRUTINIB AND RITUXIMAB IN RECURRENT/REFRACTORY (RR) PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
6. P1207: SERIAL SINGLE-CELL PROFILING OF MANTLE CELL LYMPHOMA REVEALS FUNCTIONAL AND MOLECULAR CORRELATES OF RESISTANCE TO BTK INHIBITOR-INCLUSIVE TRIPLET THERAPY
7. Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
8. Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
9. S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
10. S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
11. Protein re-surfacing of E. coli L-Asparaginase to evade pre-existing anti-drug antibodies and hypersensitivity responses
12. Cell Mass and Stiffness As Integrative Biomarkers of Cell State in Mantle Cell Lymphoma
13. Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia
14. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults
15. Distinction of lymphoid and myeloid clonal hematopoiesis
16. Abstract IA20: Aberrant leukemic developmental hierarchies and MRD-specific targeting informed by single-cell biophysical and molecular profiling
17. Signalling input from divergent pathways subverts B cell transformation
18. Signaling input from divergent pathways subverts malignant B-cell transformation
19. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults
20. Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation
21. Abstract 2990: Individualized functional approach to tailoring acute myeloid leukemia therapy
22. Abstract 2990: Individualized functional approach to tailoring acute myeloid leukemia therapy
23. Abstract 2450: Single-cell profiling reveals programs mediating oncogenic kinase-independence and minimal residual disease in BCR-ABL-rearranged acute lymphoblastic leukemia
24. Abstract 2450: Single-cell profiling reveals programs mediating oncogenic kinase-independence and minimal residual disease in BCR-ABL-rearranged acute lymphoblastic leukemia
25. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma
26. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models
27. Targeting minimal residual disease: a path to cure?
28. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
29. The next best thing
30. T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development
31. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate
32. An ED pilot intervention to facilitate outpatient acute care for cancer patients
33. High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays
34. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
35. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
36. B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development
37. The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts
38. Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma
39. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
40. Autoimmune Hemolytic Anemia
41. Use of signaling pathways as therapeutic targets for blood cancer
42. Activation of the unfolded protein response is associated with impaired granulopoiesis in transgenic mice expressing mutant Elane
43. Of Woodchucks and Prune Yards: A View of Judicial Takings from the Trenches
44. Loss of PERK Signaling Results in Impaired Granulopoiesis in Transgenic Mice Expressing Mutant Ela2.
45. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples
46. Induction of the Unfolded Protein Response but Normal Basal Granulopoiesis in Mice Expressing G192X ELA2
47. Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis
48. Granulocytic Precursors from Patients with ELA2-Mutant Severe Congenital Neutropenia Display a Transcriptional Profile Consistent with Activation of the Unfolded Protein Response.
49. The Expression Signature of M3 AML Suggests Direct and Indirect Effects of PML-RARA on Target Genes.
50. Mutations of the ELA2 Gene Found in Patients with Severe Congenital Neutropenia Induce the Unfolded Protein Response and Cellular Apoptosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.